Revelation Biosciences, Inc. (REVB) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 1.99M |
| Enterprise Value | -7.97M |
| P/E Ratio | -0.08 |
| PEG Ratio | -0 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 0.26 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | 0.92 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -0.66 |
| Return On Equity | -1.08 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | -27,058 |
| EBITDA | -9.04M |
| Net Income | -8.91M |
| Diluted EPS | -23.95 |
| Total Cash | 14.11M |
| Total Cash/Share | 4.4 |
| Total Debt | 759,044 |
| Total Debt/Equity | 0.06 |
| Current Ratio | 10.02 |
| Book Value Per Share | 4.05 |
| 52-Week Change | -88.69 |
| 52-Week High | 12.88 |
| 52-Week Low | 0.88 |
| Moving Average 50 Days | 1.08 |
| Moving Average 200 Days | 3 |
| Average Volume | 68,943 |
| Shares Outstanding | 3.91M |
| % Held by Institutions | 0.3 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
| Last Split Date | January 28, 2026 |